European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

Eisai Co.’s breakthrough Alzheimer’s drug Leqembi was cleared for use in the European Union, after the medicine was approved ...

The EU approval comes after Eisai and Biogen were given approval for a new once-monthly intravenous maintenance dose of ...

Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

The European Commission said Wednesday that it had given formal approval for Leqembi, a long-awaited new treatment for ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

From my colleague Andrew Joseph: After a bumpy road, Eisai and Biogen’s Alzheimer’s therapy Leqembi has won approval in ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer European regulators have finally approved the ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has been approved by the European Commission (EC). The ...

Eisai Co.’s breakthrough Alzheimer’s drug Leqembi was cleared for use in the European Union, after the medicine was approved in the US and Japan. The European Commission approved the drug to treat ...